Publication date: May 22, 2025
“When a cancer cell already has impaired damage repair, such as in patients with homologous recombination (HR) pathway gene mutations, the cancer cell cannot fix DNA damage. In the subgroup of 10 patients with non-uveal melanoma, the response rate and disease control rate of at least 16 weeks were 20% and 70%, respectively. “Despite these available, approved combination therapies, many patients’ disease progresses or recurs, reinforcing the critical need for new, targeted treatments,” says Dr. Kim. “Our goal is to advance this research to help guide and inform the care of patients who have limited therapeutic options. PARP inhibitors like niraparib further block the cancer cell from repairing its damaged DNA. This article has been reviewed according to Science X’s editorial process and policies . “There is much more we seek to learn.
| Concepts | Keywords |
|---|---|
| California | Advanced |
| Food | Braf |
| Mutant | Cpmc |
| Oncology | Group |
| Inhibitors | |
| Investigator | |
| Kim | |
| Melanoma | |
| Mutations | |
| Niraparib | |
| Parp | |
| Phase | |
| Treatment | |
| Tumors |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Olaparib |
| disease | MESH | uveal melanoma |
| disease | MESH | DNA damage |
| pathway | KEGG | Homologous recombination |
| pathway | REACTOME | Programmed Cell Death |
| pathway | REACTOME | DNA Repair |
| disease | MESH | tumors |
| pathway | KEGG | Melanoma |
| disease | MESH | melanoma |
| drug | DRUGBANK | Niraparib |